The Minister for the Economy sets out his conditions for the future of Doliprane

This Monday morning, Antoine Armand, Minister of the Economy, will visit the Doliprane production site in Lisieux (Calvados), accompanied by Marc Ferracci, Minister Delegate for Industry, to discuss the future of Sanofi’s iconic drug.

On Sunday October 13, Antoine Armand made his position clear: he does not rule out blocking the sale of Sanofi’s subsidiary, which produces Doliprane, to the American investment fund CD&R. He has specified that strict guarantees will have to be given to ensure that production remains in France. “I am committed to ensuring that Doliprane continues to be manufactured in France, by French workers,” he said on BFMTV. “We will demand very solid assurances.”

On Monday, the Minister will hold direct talks with employees and their representatives to obtain these guarantees. “The production of Doliprane in France is essential to our industrial, sovereign and health strategy, and this must continue,” he insisted. This possible acquisition by an American player has already provoked strong reactions in the French political landscape, with many voices calling for the country’s health sovereignty to be defended.